Oncternal Therapeutics, Inc. (ONCT)
NASDAQ: ONCT · IEX Real-Time Price · USD
9.21
+0.11 (1.21%)
May 31, 2024, 4:00 PM EDT - Market closed
Oncternal Therapeutics Revenue
Oncternal Therapeutics had revenue of $1.15M in the twelve months ending March 31, 2024, with 21.54% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $569.00K with 180.30% year-over-year growth. In the year 2023, Oncternal Therapeutics had annual revenue of $785.00K, a decrease of -47.32%.
Revenue (ttm)
$1.15M
Revenue Growth
+21.54%
P/S Ratio
23.68
Revenue / Employee
$42,630
Employees
27
Market Cap
27.26M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 785.00K | -705.00K | -47.32% |
Dec 31, 2022 | 1.49M | -2.83M | -65.47% |
Dec 31, 2021 | 4.32M | 940.00K | 27.85% |
Dec 31, 2020 | 3.38M | 950.00K | 39.18% |
Dec 31, 2019 | 2.43M | -96.00K | -3.81% |
Dec 31, 2018 | 2.52M | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 8.07M | -48.72M | -85.80% |
Dec 31, 2010 | 56.79M | 42.06M | 285.51% |
Dec 31, 2009 | 14.73M | 1.20M | 8.89% |
Dec 31, 2008 | 13.53M | 6.40M | 89.84% |
Dec 31, 2007 | 7.13M | -379.00K | -5.05% |
Dec 31, 2006 | 7.51M | 3.72M | 98.44% |
Dec 31, 2005 | 3.78M | 1.92M | 102.57% |
Dec 31, 2004 | 1.87M | - | - |
Dec 31, 2003 | 0 | - | - |
Dec 31, 2002 | 0 | - | - |
Dec 31, 2001 | 0 | - | - |
Dec 31, 2000 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionONCT News
- 3 days ago - Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire
- 24 days ago - Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results - GlobeNewsWire
- 4 weeks ago - Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results - GlobeNewsWire
- 4 weeks ago - Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire
- 2 months ago - Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer - GlobeNewsWire
- 3 months ago - Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 3 months ago - Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire